Deadly Drug-Resistant Fungus Poses Growing Threat in U.S. Hospitals and Beyond

article

A highly dangerous, drug-resistant fungus already spreading through hospitals in the United States is becoming an even greater global threat, according to a recent scientific review — though researchers say new treatments may still be possible.

The fungus, known as Candida auris, has earned the nickname “superbug fungus” because of its ability to resist multiple antifungal medications and evade the human immune system. Scientists from the Hackensack Meridian Center for Discovery and Innovation (CDI) report that the pathogen is spreading worldwide and becoming increasingly difficult to control.

The findings, published in early December in the journal Microbiology and Molecular Biology Reviews, reinforce long-standing warnings from the U.S. Centers for Disease Control and Prevention (CDC), which has classified Candida auris as an “urgent antimicrobial threat.” It is the first fungal pathogen to receive that designation.

According to the CDC, approximately 7,000 cases were identified across dozens of U.S. states in 2025, with the majority occurring in hospitals and long-term care facilities. Globally, the fungus has now been detected in at least 60 countries, highlighting its rapid international spread.

The review explains why Candida auris is so difficult to contain. Current diagnostic tools often fail to identify it quickly, allowing outbreaks to grow before infection-control measures are put in place. At the same time, treatment options remain limited, and drug development has struggled to keep pace with the fungus’s evolution.

The research was led by Dr. Neeraj Chauhan of Hackensack Meridian CDI, alongside Dr. Anuradha Chowdhary of the University of Delhi and Dr. Michail Lionakis of the National Institutes of Health. The authors emphasize the urgent need for new broad-spectrum antifungal medications, improved diagnostic tests, and additional immune-based or vaccine-supported therapies for high-risk patients.

They also stress the importance of stronger global surveillance, particularly in lower-resource countries where fungal infections are often underreported. Increased awareness and earlier detection, they say, could significantly improve patient outcomes.

First identified in 2009 from an ear infection in Japan, Candida auris has since caused outbreaks across the world. In the United States, some hospital intensive care units have been forced to temporarily shut down in order to contain its spread.

The fungus poses the greatest danger to critically ill patients, especially those on ventilators or with weakened immune systems. Some estimates suggest that up to half of infected patients may die, underscoring the severity of the threat.

Unlike many other fungi, Candida auris can survive on human skin and persist on hospital surfaces and medical equipment, allowing it to spread easily in healthcare settings. It is commonly transmitted through devices such as catheters and breathing tubes.

Compounding the danger, the fungus is frequently misdiagnosed. Its symptoms — including fever, chills, and body aches — often resemble those of other infections, delaying proper treatment and containment.

Currently, only four major classes of antifungal drugs are available, and Candida auris has already developed resistance to many of them. While several new antifungal medications are in late-stage testing or have recently been approved, experts warn that innovation has not kept up with the pathogen’s rapid adaptation.

Despite the grim outlook, researchers say there is still reason for cautious optimism.

In separate research published in December, scientists at the University of Exeter in the United Kingdom identified a potential vulnerability in Candida auris. Their study found that the fungus relies heavily on iron to survive during infection, activating specific genes to extract the nutrient from its host.

Because iron is essential for the pathogen, researchers believe drugs that block this process could weaken or stop infections — and may even allow existing treatments to be reused in new ways.

The discovery, described by one researcher as a possible “Achilles’ heel,” offers hope that targeted therapies could eventually help control this lethal fungus.

As scientists continue to study Candida auris, health officials emphasize that strict infection control, rapid detection, and sustained investment in antifungal research remain critical to preventing future outbreaks.

"Listen to me, boy: cure my twins and I'll adopt you." The billionaire laughed... and the street child only touched them; then a miracle happened..

"Listen to me, boy: cure my twins and I'll adopt you." The billionaire laughed... and the street child only touched them; then a miracle happened...

Richard Vale had everything the world admired: iron gates, private jets, a business empire built on numbers that never slept. His name opened doors. His firm ended wars in boardrooms.

But inside his mansion, silence reigned.

Since the accident, her twins—Evan and Elise—moved through life like fragile glass. Metal splints hugged their legs. Crutches scraped the marble floor. The doctors spoke in careful tones, avoiding words like “never” when they meant exactly that.

No laughing in the courtyard.

No running in the hallways.

Just medical appointments, tests, and a father drowning in guilt he couldn't buy to get out of it.

His wife, Margaret, had grown distant: not cruel, just empty. When she looked at the children, her eyes filled with a sorrow too heavy to speak aloud. When she looked at Richard, there was a question neither of them dared to ask.

Why weren't you there that day?

Then destiny arrived —not in a tailored suit, not in a luxury car.

But barefoot. Thin. Seven years old.

His name was Kai.

A child who slept under park benches and spoke to the sky as if the sky were answering him.

The gala night glittered like a lie. The chandeliers burned brightly. The champagne flowed. The donors smiled with rehearsed pity as the twins were wheeled into the ballroom: symbols of tragedy wrapped in wealth.

Richard smiled all night. He nodded. He thanked everyone.

Until something inside him broke.

He saw Kai near the back —silent, invisible— looking at the twins with an expression that was not one of pity.

And Richard, drunk with pain and arrogance, said the words that would either destroy him… or redeem him.

"Look, kid," she laughed loudly, her voice echoing through the room. "Heal my children and I'll adopt you. How about that? Now that would be a miracle, wouldn't it?"

Some guests giggled. Others froze.

Kai didn't laugh.

He advanced calmly, as if the marble floor belonged to him.

"Can I try?" he asked gently.

The room fell silent.

Richard made a dismissive gesture with his hand.

—Go ahead. Do me a favor.

Kai knelt before the twins. He didn't ask their names. He didn't touch the splints. He didn't say a word anyone would recognize.

She simply closed her eyes… and gently placed her hands on their knees.

The air changed.

Not dramatically. Just… strange. Like the moment before a storm.

So-

Evan's crutch slipped from his hand and fell to the ground with a thud.

"I-I... I feel hot," Evan whispered, his eyes wide. "Dad... it doesn't hurt."

Elise stood up.

One step.
Then another.

A collective gasp tore through the room.

Margaret screamed.

Richard couldn't breathe.

The twins stood there—trembling, crying, standing—while the guests recoiled as if witnessing something forbidden.

And Kai?

Kai staggered.

He collapsed.

The doctors rushed toward him, shouting orders. Security panicked. Richard fell to his knees beside the child.

"What did you do?" she demanded, her voice breaking.

Kai smiled weakly.

—I shared.

That night, the tests showed the impossible: nerve activity restored, damage reversed beyond any medical explanation. The twins slept peacefully for the first time in years.

Kai lay unconscious in a private room at the hospital.

And Vivien Vale —Richard's sister— made her move.

He called lawyers. Doctors. Board members.

"It's a fraud," he insisted. "Or it's dangerous. We can't let it stay."

When Kai finally woke up, Vivien was alone by his bed.

"You don't belong here," he said coldly. "Tell me your price. I'll make you disappear."

Kai looked at her calmly.

—I already have a home.

—You live on the street.

—I used to live where I was needed —he replied—. Now I'm here.

Vivien smiled barely, her smile thin and sharp.

—Do you think my brother will choose you over the family name?